EXEL logo

EXEL
Exelixis Inc

12,195
Mkt Cap
$10.75B
Volume
779.00
52W High
$49.62
52W Low
$32.38
PE Ratio
14.88
EXEL Fundamentals
Price
$41.41
Prev Close
$41.27
Open
$41.80
50D MA
$42.99
Beta
0.46
Avg. Volume
2.89M
EPS (Annual)
$2.78
P/B
5.03
Rev/Employee
$2.15M
$11,425.42
Loading...
Loading...
News
all
press releases
Private Client Services LLC Takes $1.99 Million Position in Exelixis, Inc. $EXEL
Private Client Services LLC bought a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Strategic Investment Advisors MI Buys 27,659 Shares of Exelixis, Inc. $EXEL
Strategic Investment Advisors MI lifted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 486.6% during the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat·5d ago
News Placeholder
Here's Why Exelixis (EXEL) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·6d ago
News Placeholder
L2 Asset Management LLC Invests $3.36 Million in Exelixis, Inc. $EXEL
L2 Asset Management LLC purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the...
MarketBeat·7d ago
News Placeholder
Exelixis, Inc. $EXEL Shares Acquired by Clark Capital Management Group Inc.
Clark Capital Management Group Inc. increased its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 14.3% during the third quarter, according to the company in its most recent Form...
MarketBeat·8d ago
News Placeholder
Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink
Exelixis (NASDAQ:EXEL) executives and investors spent part of the discussion at a Leerink event focusing on recent renal cell carcinoma (RCC) data, evolving treatment sequencing debates, and the...
MarketBeat·8d ago
News Placeholder
Exelixis Highlights CABOMETYX Growth, Zanzalintinib PDUFA and Pipeline Strategy at Barclays Conference
Exelixis (NASDAQ:EXEL) described its current commercial trajectory, late-stage clinical programs, and strategic priorities during a discussion at a Barclays event featuring Senior Vice President of...
MarketBeat·8d ago
News Placeholder
Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference
Exelixis (NASDAQ:EXEL) detailed its commercial momentum for cabozantinib and outlined key upcoming clinical catalysts for zanzalintinib during a discussion at the Citizens Life Sciences Conference...
MarketBeat·8d ago
News Placeholder
Capital Impact Advisors LLC Boosts Stock Position in Exelixis, Inc. $EXEL
Capital Impact Advisors LLC lifted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 15.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange...
MarketBeat·9d ago
News Placeholder
Exelixis, Inc. $EXEL Stake Raised by South Street Advisors LLC
South Street Advisors LLC raised its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 127.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange...
MarketBeat·10d ago
<
1
2
...
>

Latest EXEL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.